Yahoo · Nov 12, 2025
TherapeuticsMD: Q3 Earnings Snapshot
BOCA RATON, Fla. AP) — TherapeuticsMD Inc. TXMD) on Wednesday reported earnings of $152,000 in its third quarter.
NASDAQ · TXMD
TherapeuticsMD, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$2.01
Up+$0.01 (+0.50%)
Updated Oct 9, 2026, 11:58 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 21.53M
- P/E ratio
- -46.9
- Dividend yield
- 0.00%
- 52-week range
- $1.03 – $2.95
- Volume
- 13.81K
- Avg. volume
- 226.46K
Price performance · TXMD
TXMD price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
TXMD closed at $2.01 after 21 trading sessions, down 4.29% for the selected period.
- Last close
- $2.01
- Period change
- -4.29%
- Period low
- $2.00
- Period high
- $2.19
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $1.9993 | $2.03 | $1.99 | $2.01 | 13.81K |
| Oct 7, 2026 | $2.0032 | $2.0395 | $1.99 | $2.00 | 42.52K |
| Oct 6, 2026 | $2.01 | $2.06 | $2.0059 | $2.02 | 8.38K |
| Oct 5, 2026 | $2.02 | $2.08 | $2.01 | $2.01 | 19.39K |
| Oct 2, 2026 | $2.001 | $2.06 | $2.00 | $2.05 | 9.91K |
| Oct 1, 2026 | $2.02 | $2.06 | $2.00 | $2.03 | 20.37K |
| Sep 30, 2026 | $2.095 | $2.1209 | $2.03 | $2.03 | 7.25K |
| Sep 29, 2026 | $2.10 | $2.1046 | $2.04 | $2.04 | 8.03K |
| Sep 28, 2026 | $2.03 | $2.09 | $2.03 | $2.09 | 12.12K |
| Sep 25, 2026 | $2.13 | $2.13 | $2.04 | $2.05 | 13.8K |
| Sep 24, 2026 | $2.095 | $2.155 | $2.095 | $2.13 | 7.47K |
| Sep 23, 2026 | $2.17 | $2.20 | $2.11 | $2.17 | 29.92K |
| Sep 22, 2026 | $2.08 | $2.17 | $2.08 | $2.16 | 17.2K |
| Sep 21, 2026 | $2.18 | $2.185 | $2.04 | $2.10 | 52.26K |
| Sep 18, 2026 | $2.185 | $2.19 | $2.18 | $2.19 | 7.97K |
| Sep 17, 2026 | $2.18 | $2.2092 | $2.18 | $2.18 | 7.18K |
| Sep 16, 2026 | $2.16 | $2.19 | $2.135 | $2.18 | 27.2K |
| Sep 15, 2026 | $2.162 | $2.165 | $2.135 | $2.16 | 20.91K |
| Sep 14, 2026 | $2.16 | $2.17 | $2.15 | $2.16 | 14.27K |
| Sep 11, 2026 | $2.09 | $2.1831 | $2.09 | $2.16 | 28.41K |
| Sep 10, 2026 | $2.12 | $2.17 | $2.07 | $2.10 | 20.13K |
Latest TXMD news
The latest Smart Investors Daily articles mentioning TXMD.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TXMD research
Overview
Company profile and research snapshot.
Company profile
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2023 | Cantor Fitzgerald | Neutral | — |
| Jan 11, 2023 | Cantor Fitzgerald | Neutral | — |
| Jul 13, 2022 | Cantor Fitzgerald | Neutral | — |
| Jun 7, 2022 | HC Wainwright & Co. | Neutral | — |
| May 6, 2022 | Cantor Fitzgerald | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Nov 12, 2025
TherapeuticsMD Announces Third Quarter 2025 Financial Results
BOCA RATON, Fla., November 12, 2025--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025.
businesswire.com · Nov 12, 2025
TherapeuticsMD Announces Third Quarter 2025 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
